ANTENGENE

Antengene Corporation Limited
德琪醫藥有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6996)

(1) RESIGNATION OF EXECUTIVE DIRECTOR AND CHIEF FINANCIAL OFFICER
(2) APPOINTMENT OF EXECUTIVE DIRECTOR
(3) APPOINTMENT OF CHIEF BUSINESS OFFICER
(4) CHANGE OF AUTHORIZED REPRESENTATIVE AND PROCESS AGENT

RESIGNATION OF EXECUTIVE DIRECTOR AND CHIEF FINANCIAL OFFICER

The board (the "**Board**") of directors (the "**Directors**" and each, a "**Director**") of Antengene Corporation Limited (the "**Company**", together with its subsidiaries, the "**Group**") announces that Mr. Donald Andrew Lung ("**Mr. Lung**") has tendered his resignation as an executive Director and the chief financial officer (the "**CFO**") of the Company with effect from August 1, 2026 in order to pursue other career opportunities.

Mr. Lung has confirmed that (i) he has no disagreement with the Board; and (ii) there are no matters with respect to his resignation that need to be brought to the attention of the shareholders of the Company or The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**").

The Board would like to take this opportunity to express its gratitude to Mr. Lung for his valuable contribution to the Company during his tenure of office.

APPOINTMENT OF EXECUTIVE DIRECTOR

The Board is pleased to announce that Dr. Bing Hou ("**Dr. Hou**") has been appointed as an executive Director with effect from August 1, 2026.

The biographical details of Dr. Hou are set out below:

Dr. Bing Hou (侯冰), aged 42, has over 16 years of experience in basic research and drug research and development. Dr. Hou joined the Company as Drug Discovery Director in April 2019 and was appointed as the chief scientific officer of the Company on May 20, 2026. He has been a key member of the Company's scientific leadership team. During his tenure, he has built and led a high-caliber discovery organization, helped guide the Company's R&D initiatives, advanced internally discovered programs into clinical development, and played an important role in establishing newly developed proprietary platforms designed to support future innovation programs.

Prior to joining the Company, Dr. Hou worked in the Multitude Therapeutics drug discovery team of Abmart Inc. from December 2015 to April 2019.

Dr. Hou received his Doctor of Philosophy in Biomedicine from the University of Leeds in the United Kingdom. He has published multiple high-impact research papers in leading journals including Nature, Science Advances, and Cancer Research. He has filed more than 40 patent applications for novel therapeutics. As an inventor and/or principal leader, he has advanced multiple first-in-class or best-in-class drug candidates into various stages of clinical development.

Dr. Hou will enter into a service contract with the Company with an initial term of three years commencing from August 1, 2026, subject to (i) retirement from office and re-election at the next annual general meeting of the Company; and (ii) retirement by rotation and re-election at least once every three years, in accordance with the articles of association of the Company and the corporate governance code as set out in Appendix C1 to the Rules Governing the Listing of Securities on the Stock Exchange (the "**Listing Rules**"). According to the terms of Dr. Hou's appointment, he will not receive any director's fee in relation to his additional role as a Director.

As at the date of this announcement, Dr. Hou is interested in 244,080 shares and 2,128,257 underlying shares (comprising 1,983,000 share options and 145,257 unvested share awards) of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Save as disclosed above and as at the date of this announcement, Dr. Hou has confirmed that he (i) does not have any relationship with any Directors, senior management or substantial shareholders or controlling shareholders (as defined in the Listing Rules) of the Company; (ii) does not hold any other position in the Company or other members of the Group; (iii) has not held any directorship in public companies with the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; (iv) has no any other major appointments or professional qualifications; and (v) has no any other interest in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Save as disclosed above and as at the date of this announcement, there is no other information in relation to Dr. Hou which is required to be disclosed pursuant to the requirements set out in Rules 13.51(2)(h) to (v) of the Listing Rules, nor are there any other matters which need to be brought to the attention of the shareholders or the Stock Exchange relating to Dr. Hou's appointment.

APPOINTMENT OF CHIEF BUSINESS OFFICER

The Board is also pleased to voluntarily announce that Ms. Rui Guo (郭睿) ("**Ms. Guo**") has been appointed as the chief business officer of the Company with effect from August 1, 2026.

Ms. Guo has been with the Company since 2017, and has demonstrated leadership across multi-functions, including business development, corporate strategy, project leadership and alliance management. Most recently, the successful partnership she led included the collaboration with UCB and she has been instrumental in driving the Company's business and corporate development initiatives. She will continue to oversee the Company's business development and strategic partnership activities in her new role.

Ms. Guo holds a Master of Science in Management Science and Engineering from Columbia University in New York and a bachelor's degree in Statistics from Fudan University (復旦大學) in China.

CHANGE OF AUTHORIZED REPRESENTATIVE AND PROCESS AGENT

Following Mr. Lung's resignation as an executive Director, Mr. Lung will also cease to be an authorized representative of the Company under Rule 3.05 of the Listing Rules (the "**Authorized Representative**") and the authorized representative of the Company for accepting service of process and notices on behalf of the Company in Hong Kong under Part 16 of the Companies Ordinance (Chapter 622 of the Laws of Hong Kong) and Rule 19.05(2) of the Listing Rules (the "**Process Agent**"), both with effect from August 1, 2026.

Dr. Hou has been appointed as an Authorized Representative with effect from August 1, 2026.

Meanwhile, Mr. Yig Jun Jon Yau (丘奕駿) ("**Mr. Yau**") has been appointed as the Process Agent with effect from August 1, 2026.

The Board would like to extend its warm welcome to Dr. Hou, Ms. Guo and Mr. Yau on their respective new appointments.

By the order of the Board
Antengene Corporation Limited
Dr. Jay Mei
Chairman

Hong Kong, July 31, 2026

As at the date of this announcement, the Board comprises Dr. Jay Mei and Mr. Donald Andrew Lung as executive Directors; and Ms. Jing Qian, Mr. Sheng Tang and Dr. Rafael Fonseca as independent non-executive Directors.